This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Biotech- and healthcare-related startups led the way as those companies dominate the list, taking a vast majority of spots. DDN , $300M, data storage: Data is the big-money game right now. Of course this is far from the only play the Blackstone Group has made in the data sector. billion to develop data centers in Spain.
startups raised half a billion dollars apiece, and another eight raised $100 million or more, with industries from cybersecurity to biotech to AI represented. The company is a so-called “neocloud” — a data center firm providing outsourced cloud computing for those looking to build AI. billion in over 900 rounds, per Crunchbase data.
The new fund is just the latest example of investor excitement about healthcare- and biotech-related uses for AI. Venture funding to AI-related biotech and healthcare startups hit only $4.8 billion through early December, per Crunchbase data. billion was raised by AI-related biotech/healthcare related startups.
Commerce Department said Wednesday it is imposing new export controls on biotechnology equipment and related technology because of national security concerns tied to artificial intelligence and data science. imposing new export controls on biotech equipment over China concerns appeared first on OODAloop.
Biotech was one of the most fortunate. billion, according to Pitchbook data. Those figures fell short of the 1,415 biotech deals struck in 2021 worth a total of $39 billion. Compared to 2020’s more conservative 1,143 biotech deals worth $29.6 biotech deals also set new records in 2022 for both median deal size, $33.5
Given this success, many biotech companies are looking to move on to the next phase of their organizational growth — which may mean an initial public offering. As optimism grows, market conditions may stabilize in 2025 — particularly in the wake of the recent interest rate cuts — and more biotech companies may consider offerings.
Biologists and other scientists are confronted these days with a deep sea of data and a bewildering panoply of tools to apply to it — many of which require a specialist to operate. Fundamentally, the issue is just that scientists are not all data scientists. “Like AlphaFold — it’s a very heavy model.
The surge was driven by large funds leading supergiant rounds in capital-intensive businesses in areas such as artificial intelligence, data centers and energy. Those 50 companies that raised large rounds in October ranged across many sectors, including AI, data centers, nuclear energy, biotech, semiconductors, fintech, space and robotics.
JP Morgan’s announcement comes at a time when, in the words of B Capital general partner and head of healthcare Robert Mittendorff M.D, “public market biotechs are dramatically down as interest rates rise and the focus on near-term development outweighs the promise of longer-term results and approvals.”
That’s why we weren’t very surprised when a slew of investors told us they rarely see a biotech startup that doesn’t incorporate AI in some form or other these days. But despite becoming quite the buzzword, AI’s apparent ubiquity in biotech isn’t actually driving deal flow or higher valuations.
Medical and biotech had a strong showing at Y Combinator’s latest demo day , with nearly a dozen companies in the space catching my eye. LiliumX is taking the algorithmic approach to generating potential antibody stuctures that could be effective, as many AI-informed biotech companies have before it. Startups take on big pharma.
Biotech offerings, while more plentiful, are also running well below prior highs. Below, we pick out winners and losers for venture-backed tech and biotech companies, focusing on large- and medium-sized IPOs. Top biotech performers Biotech companies that debuted on public markets this year also saw plenty of ups and downs.
Improving the diversity of global genomic data could hasten medical breakthroughs — and that’s the goal of Gen-t , a Brazilian startup working to infuse biotech with genetic data from the country’s population. Without diversifying that data, Pereira said it can’t lead to greater medical advancements.
Understanding the Unique Challenges in Recruiting for Biotech and Life Sciences The recruitment process in the biotech and life sciences industry comes with its own set of unique challenges. One of the primary obstacles is the need for more highly skilled and qualified talent.
” In a data-driven piece that looks at post-money valuations, deal sizes and dilution rates going back to 2012, Mitchem says we’re now heading into a new era where the tech industry will embrace “growth at reasonable costs.” 6 investors discuss why AI is more than just a buzzword in biotech.
6 questions investors should ask when evaluating psychedelic biotech companies. 6 questions investors should ask when evaluating psychedelic biotech companies. Gogoro’s public debut could supercharge EV battery swapping across the globe. Image Credits: Yarygin (opens in a new window) / Getty Images.
But sometimes key data points are lost in even those more specific venture capital data dives. Is the Boston area’s software-and-biotech focus doing better than, say, the Bay Area’s startup machine? TechCrunch spends time each quarter covering the startup markets of the world.
Eikon Therapeutics , $351M, biotech: Eikon Therapeutics raised one of the biggest biotech rounds thus far in 2025. The round is the second biggest for a biotech startup this year, behind only London-based Verdiva Bio , a company creating treatments for obesity and cardiometabolic diseases that raised a $411 million Series A in January.
(tied) Crusoe Energy Systems , $500M, energy: Back in 2022, the Denver-based company was helping power Bitcoin mining by harnessing natural gas that is typically burned during oil extraction and putting it toward powering the data centers needed for mining — raising a $350 million Series C equity round led by G2 Venture Partners , at $1.75
Related reading: The Weeks Biggest Funding Rounds: Data Storage And Lots Of Biotech Illustration: Dom Guzman Also last week, Palo Alto, California-based Hippocratic AI , which develops a safety-focused large language model for healthcare, safety and accuracy, raised a $141 million Series B valuing the company at $1.6
The appetite for genomic data continues to rise in the field of biotech and pharmaceutical research, but cost is still a factor — even sequencing a full genome now costs as little as $1,000. I asked Almogy what he felt were the areas of the biotech and medical industry that will benefit most from this new capability.
billion globally went to companies applying advances in artificial intelligence to health-related areas such as medical services and pharmaceutical development, per Crunchbase data. Last year, more than $7.5 This year is off to a brisk start as well, with nearly $1.68 billion already invested.
This year is shaping up as the first we’ve seen in which biotech and healthcare startups receive a majority of U.S. So far in 2024, biotech and health companies have pulled in around $5.6 billion across 110 Series A rounds, per Crunchbase data. Of the 10 largest Series A rounds this year, six are biotechs.
Venture money wasnt concentrated in just one sector, as VCs invested in everything from artificial intelligence to biotech to energy. tied) Retro Biosciences , $1B, biotech: AI can do a lot startup Retro Biosciences thinks it can even help us live longer. tied) DDN , $300M, data storage: Data is the big-money game right now.
Overall startup funding in 2024 reached close to $314 billion compared to $304 billion in 2023 up around 3%, based on an analysis of Crunchbase data. billion in 2023 Crunchbase data shows. Infrastructure and data provisioning to manage and operate AI grew. Data reported is as of Jan. billion invested a year ago.
By Caleb Appleton Having invested in the biotech space since before it had a name, Ive seen life sciences investors steer founders toward a therapeutics pipeline in hopes of securing the payout of a winning drug or medical device. Is there a business model to support the technology?
Data is the big-money game right now. Private equity giant Blackstone Group is making a $300 million strategic investment into DDN , valuing the Chatsworth, California-based data storage company at $5 billion. Big money Of course this is far from the only play the Blackstone Group has made in the data sector.
EarthOptics helps farmers look deep into the soil for big data insights. And the mosquito treatment could be commercialized as well as a naturally derived pesticide that’s more effective than many out there today to which the insect has developed a resistance.
French biotech company WhiteLab Genomics has raised $10 million in funding for an AI platform designed to aid the discovery and development of genomic therapies. Show me the data. “We also partner with specialized institutions to enrich the models with additional non-public data,” Del Bourgo added.
Hightouchs AI Decisioning product allows marketers to synchronize data and then let AI agents decide what messages and/or experiences to send each customer personalizing the marketing effort. The San Francisco-based startup plans to use the money to push its new platform that is powered by what else? artificial intelligence.
Digital drug discovery in general means large-scale analysis of biological data like genes, gene expression, protein structures, binding sites, things like that. So a new crop of biotech companies have worked to integrate these aspects. .” 2021 should be a banner year for biotech startups that make smart choices early.
Suggestions like “listen to your customers” and “make data-driven decisions” are so general, they’re hard to implement. “While excessive or unhelpful customer data can clog content pipelines, the right information can power hyper-personalization at scale,” he writes.
To illustrate, we used Crunchbase data to examine IPO and M&A exits since 2023 for six firms that regularly top our active lead investor rankings. Crunchbase data showed that out of all lead investments from these firms, just 10 portfolio companies have gone public since 2023. billion acquisition of data protection startup Own Co.
The software Form Bio developed is meant to bring a suite of workflow solutions to the computational biology space, which uses data and modeling to understand biological systems and includes sectors like gene therapy and biotech.
The firm has taken part in three of the largest fundraises by AI companies in the past few months, per Crunchbase data. The San Francisco-based company which helps businesses process, analyze and manage large amounts of data quickly and efficiently using tools like AI and machine learning is now the fourth-most highly valued U.S.
Dear Sophie, We have a stealth early-stage biotech startup. Budding Biotech. I generally recommend having almost like a teaser version of the deck with enough data and information to give us a sense of where you are in terms of the journey of your company,” said Jomayra Herrera, a partner at Reach Capital.
Just three years after its founding, biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80 million. “I hope it doesn’t sound corny, but we don’t have the luxury to move more slowly,” explained Immunai co-founder and CEO Noam Solomon in an interview.
AI and biotech were the biggest areas for funding, led by Grammarlys $1 billion raise, and a reported $600 million financing for brain implant developer Neuralink. This is a weekly feature that runs down the weeks top 10 announced funding rounds in the U.S. Check out the biggest funding rounds of last week here.
So, I ended up getting my master’s in computer engineering and specializing in data assurance and forensics. That’s where my love of security also began: Learning how data is important, how data belongs to the owner and how it should be protected…especially with the other mission of digitalization. Then I started working.
billion valuation in April, data security startup Cyera closed another $300 million windfall at more than twice its previous valuation. The startup has an AI-powered data security platform that helps security teams at companies understand what data they have and how it’s used, as well as how to secure it across a complex digital landscape.
Finally, Astera Labs which provides data and memory connectivity solutions for some of the biggest chipmakers in the world had a successful IPO even though its shares have tailed off its highs. The startup gives access to the highly sought after AI chips from Nvidia through its more than two dozen data centers.
billion valuation in April, data security startup Cyera last month closed another $300 million windfall at more than twice its previous valuation. Of course, the reliance on data has only become stronger as companies drive AI initiatives. Overall, this has been a good year for robotics startups receiving funding. billion in 2021.
Conventional electronic media like flash drives and hard drives require energy consumption to process a vast amount of high-density data and information overload and are vulnerable to security issues due to the limited space for storage. There is also an expensive cost issue when it comes to transmitting the stored data.
Latigo Biotherapeutics , $150M, biotech: Many patients shy away from taking opioids while many doctors are reluctant to prescribe the painkillers. Curevo , $110M, biotech: Seattle-based Curevo, a clinical-stage biotechnology company developing vaccinations for infectious disease, closed a $110 million Series B led by new investor Medicxi.
We organize all of the trending information in your field so you don't have to. Join 49,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content